Glaxo Names Duke Researcher to Head Genetics Effort | GenomeWeb

RESEARCH TRIANGLE PARK, N.C.--Duke University researcher Allen Roses has been named director of Glaxo Wellcome's $48 million international genetics program. He will be based in the company's U.S. headquarters here and continue working at Duke as an adjunct professor. Previously, Glaxo Wellcome had funded Roses's Alzheimers research.

The Glaxo Wellcome genetics program employs 150 researchers in laboratories in the U.S., the U.K., and Switzerland. The company has said it expects the size of the department to double over the next 18 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.